Press Releases

Date Title and Summary View
Toggle Summary Abhay Joshi, PhD, MBA, Chief Operating Officer of Revance, Honored by the American Institute for Medical and Biological Engineering (AIMBE)
Abhay Joshi, PhD, MBA, Chief Operating Officer of Revance, Honored by the American Institute for Medical and Biological Engineering (AIMBE) NEWARK, Calif., April 4, 2016 - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and
View HTML
Toggle Summary BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
- Poster Abstract at TOXINS 2017 Receives Honors - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentation of clinical data from the
View HTML
Toggle Summary Medicis and Revance Announce Agreement for Development of Next-Gen Neurotoxin
CONTACT: Medicis Pharmaceutical Corporation Kara Stancell Executive Director, Investor Relations & Corporate Communications (480) 291-5854 Revance Therapeutics, Inc. Niquette Hunt Senior Vice President, Commercial Development (510) 742-3464 SCOTTSDALE, Ariz. and NEWARK, Calif.
View HTML
Toggle Summary Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
View HTML
Toggle Summary Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company's two pivotal SAKURA Phase 3
View HTML
Toggle Summary Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced presentation of clinical data from the company's two pivotal SAKURA Phase 3 trials of
View HTML
Toggle Summary Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery
- RT002 injectable 40-unit dose under study for the treatment of glabellar lines demonstrated statistical and clinical superiority over BOTOX* Cosmetic for a range of efficacy outcomes and achieved six-month duration of effect - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc.
View HTML
Toggle Summary Revance Annouces Series D Financing
Revance Annouces Series D Financing CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – January 4, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced the first $25M closing of a $35 million Series D financing.
View HTML
Toggle Summary Revance Announces $45 Million Financing
Revance Announces $45 Million Financing CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – June 10, 2011 – Revance Therapeutics, Inc. (“Revance”) today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures
View HTML
Toggle Summary Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting
- Additional Presentation Affirms Use of Patient Questionnaires in Assessing Frown Lines - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools